美得威
南京先声药业 返回


Nanjing Simcere Pharmaceutical Group

    

    To establish a company that would in turn help create a healthier China, Simcere was founded in 1995. The company has swiftly evolved from being a pure distributor of pharmaceutical products to become a leading manufacturer and supplier of drugs in the rapidly growing China pharmaceutical market. It now have six certified Good Manufacturing Practices ("GMP") manufacturing facilities, two nationwide sales and marketing subsidiaries, a research and development center and over 3,000 employees. In recent years, Simcere has continued to refine its strategy to focus on the development of first-to-market generic and innovative pharmaceuticals. It currently manufactures and sells 39 principal pharmaceutical products and is the exclusive distributor of three additional pharmaceuticals that are manufactured by independent third parties but marketed under its brand. In addition, its innovative anti-cancer medication Endu was granted an invention patent in China and was the first recombinant human endostatin injection approved for sale in China. And its generic anti-stroke medication Bicun was the first edaravone injection, a type of neuroprotective pharmaceutical compound, approved for sale in China. Going forward, Simcere wishes to become a leading Chinese pharmaceutical company by providing innovative medicines that will reshape the future of the pharmaceutical industry in China.



南京玄武区玄武大道699-18号创业社区27幢3楼    电话:025-85553968 025-85553958    邮箱:market@mediv.com.cn    微信号:NJ-MEDIV    苏ICP备11083608号-1 技术支持: 小巨人